## **Supplemental Material**

Title: Implications of the use of algorithmic diagnoses or Medicare claims to ascertain dementia

Authors: Melinda C. Power<sup>1</sup>, Kan Z. Gianattasio<sup>1</sup>, Adam Ciarleglio<sup>2</sup>

**Affiliations**: <sup>1</sup>Department of Epidemiology, Milken Institute School of Public Health, George Washington University, Washington, DC, <sup>2</sup>Department of Biostatistics and Bioinformatics, Milken Institute School of Public Health, George Washington University, Washington, DC

## **Supplemental Methods**

ICD-9-CM codes used to identify dementia in Medicare data (originally from Taylor et al. 2009 [1]):

331.0 Alzheimer's disease 331.1 Pick's disease 331.2 Senile degeneration of the brain 331.7 Cerebral degeneration in diseases classified elsewhere 290.0 Senile dementia, uncomplicated 290.1 Presenile dementia (brain syndrome w/presenile dementia) 290.10 Presenile dementia, uncomplicated 290.11 Presenile dementia, w/delirium 290.12 Presenile dementia, w/delusional features 290.13 Preseniledementia, w/depressive features 290.20 Senile dementia, w/delusional features 290.21 Senile dementia, w/depressive features 290.3 Senile dementia, w/delirium 290.40 Arteriosclerotic dementia, uncomplicated 290.41 Arteriosclerotic dementia, w/delirium 290.42 Arteriosclerotic dementia, w/ delusional features 290.43 Arteriosclerotic dementia, w/ depressive features 294.0 Amnestic syndrome (Korsakoff's psychosis or syndrome, nonalcoholic) 294.1 Dementia in conditions classified elsewhere 294.8 Other specified organ brain syndrome (chronic) 797 Senility without mention of psychosis

1. Taylor DH, Jr., Ostbye T, Langa KM, Weir D, Plassman BL. The accuracy of Medicare claims as an epidemiological tool: the case of dementia revisited. J Alzheimers Dis. 2009;17(4):807-15.

Supplemental Table 1.	upplemental Table 1. Performance metrics for each algorithm derived through comparison to Wave A dementia diagnoses in the common and Medicare sa										
	Common Sample (n=608)										
	H-W	L-K-W	Crimmins	Hurd	Wu	Expert Model	LASSO	Modified Hurd	Medicare 3- year		
Overall											
Sensitivity	41%	56%	64%	63%	63%	79%	89%	80%	47%		
Specificity	100%	97%	97%	99%	98%	92%	91%	95%	98%		
Accuracy	93%	92%	93%	94%	94%	90%	91%	93%	91%		
Under Age 80											
Sensitivity	47%	57%	56%	49%	51%	62%	84%	64%	40%		
Specificity	100%	98%	99%	100%	99%	97%	94%	98%	99%		
Accuracy	97%	95%	96%	97%	96%	95%	94%	96%	96%		
Age 80 and over											
Sensitivity	38%	55%	68%	69%	69%	86%	91%	87%	50%		
Specificity	100%	95%	95%	96%	96%	81%	84%	87%	95%		
Accuracy	86%	86%	88%	90%	90%	82%	85%	87%	85%		
Non-Hispanic Black											
Sensitivity	43%	69%	73%	90%	63%	88%	97%	90%	38%		
Specificity	98%	84%	96%	96%	94%	91%	87%	88%	98%		
Accuracy	87%	81%	91%	95%	88%	90%	89%	89%	85%		
Non-Hispanic White											
Sensitivity	41%	54%	62%	59%	63%	77%	87%	78%	49%		
Specificity	100%	98%	98%	99%	99%	92%	91%	95%	98%		
Accuracy	93%	93%	94%	94%	95%	91%	91%	93%	92%		
Male											
Sensitivity	26%	44%	54%	50%	42%	63%	70%	69%	39%		
Specificity	100%	95%	97%	98%	98%	93%	92%	94%	97%		
Accuracy	92%	90%	93%	93%	93%	90%	90%	91%	91%		
Female											
Sensitivity	49%	61%	68%	69%	73%	87%	98%	85%	51%		
Specificity	100%	98%	98%	99%	98%	92%	90%	95%	98%		
Accuracy	93%	93%	94%	95%	95%	91%	91%	94%	92%		
< High School											
Sensitivity	35%	57%	62%	67%	72%	79%	89%	83%	33%		

Specificity	99%	92%	94%	97%	95%	87%	86%	93%	99%
Accuracy	88%	86%	88%	92%	91%	86%	86%	91%	85%
High School +									
Sensitivity	46%	54%	65%	60%	56%	78%	89%	77%	60%
Specificity	100%	98%	99%	99%	100%	94%	93%	96%	97%
Accuracy	95%	94%	96%	95%	95%	93%	93%	94%	94%
Diabetes									
Sensitivity	29%	42%	53%	61%	68%	73%	82%	82%	25%
Specificity	100%	95%	97%	99%	99%	93%	93%	95%	99%
Accuracy	93%	89%	92%	95%	96%	91%	92%	94%	89%
No Diabetes									
Sensitivity	44%	58%	66%	63%	62%	80%	90%	80%	52%
Specificity	100%	97%	97%	98%	98%	92%	91%	95%	97%
Accuracy	93%	93%	94%	94%	94%	90%	91%	93%	92%
1+ IADL Limitation									
Sensitivity	60%	74%	83%	86%	85%	98%	100%	99%	54%
Specificity	99%	88%	84%	92%	93%	74%	73%	82%	97%
Accuracy	84%	82%	84%	90%	90%	83%	83%	88%	80%
No IADL Limitation									
Sensitivity	6%	21%	27%	18%	20%	42%	68%	44%	33%
Specificity	100%	98%	100%	100%	99%	95%	94%	97%	98%
Accuracy	95%	94%	96%	95%	95%	92%	93%	94%	95%
Self-respondent									
Sensitivity	14%	31%	42%	32%	36%	62%	79%	63%	34%
Specificity	100%	97%	99%	99%	99%	93%	93%	95%	98%
Accuracy	94%	93%	95%	94%	95%	91%	92%	93%	93%
Proxy respondent									
Sensitivity	73%	84%	89%	98%	94%	98%	100%	100%	63%
Specificity	99%	75%	49%	83%	76%	45%	24%	72%	100%
Accuracy	81%	81%	76%	93%	88%	81%	75%	91%	76%
All estimates are weigh	ited using Wave A	A ADAMS samplir	ng weights.						

Supplemental Table 2. Dementia prevalence by ascertainment strategy and participant characteristics											
	Common Sample, n=608										
										Any FFS	
	In-Person		E	kisting Algorit	hms		Algorithr	ns Designed to	o Minimize	Medicare	
	Evaluation						Race/E	thnicity Differ	ences in		
		11.54/		<b>C</b> -1		1.1.1	Sens	tivity and Spe		Maralia and D	
	ADAIVIS	H-W	L-K-VV	Crimmins	Hurd	l wa	Expert	LASSO	IVIODITIED	Medicare 3-	
				Domont	 ia Brovalanco	05% Confider			Hura	year	
Overall			0.401	Dement				40.000	4.4.404		
	11.00( (0.50)	5.0%	9.4%	9.8%	8.7%	8.9%	16.3%	18.3%		7 00/ /0 00/	
	11.8% (9.5%,	(3.8%,	(7.7%,	(8.0%,	(6.9%,	(7.1%,	(13.5%,	(15.2%,	(11./%,	7.9% (6.0%,	
	14.5%)	6.6%)	11.5%)	12.0%)	10.9%)	11.1%)	19.4%)	21.8%)	16.9%)	10.3%)	
Age											
Under Age 80 (ref)		2.8%	5.5%	4.5%	3.2%	3.7%	6.3%	10.0%	5.4%		
	5.7% (3.6%,	(1.5%,	(3.8%,	(2.9%,	(1.8%,	(2.2%,	(4.3%,	(7.1%,	(3.6%,	3.3%	
	9.0%)	5.1%)	8.0%)	7.0%)	5.5%)	6.1%)	9.2%)	14.0%)	7.9%)	(1.8%, 5.7%)	
Age 80 and over	22.9%	9.1%	16.6%	19.6%	18.9%	18.5%	34.6%	33.6%	30.1%	15.6%	
	(18.2%,	(7.0%,	(13.2%,	(15.6%,	(14.8%,	(14.5%,	(28.3%,	(27.4%,	(24.5%,	(11.5%,	
	28.4%)	11.9%)	20.7%)	24.2%)	23.8%)	23.3%)	41.5%)	40.3%)	36.4%)	20.8%)	
PR (95%CI)		3.26						/			
	3.99 (2.41,	(1.68,	3.00 (1.94,	4.35 (2.64,	5.91 (3.26,	4.99 (2.87,	5.46 (3.60,	3.35 (2.27,	5.61 (3.64,	4.81 (2.52,	
	6.60)	6.31)	4.63)	7.16)	10.71)	8.68)	8.30)	4.97)	8.66)	9.17)	
Gender											
Male (ref)		2.9%	8.5%	8.4%	6.8%	5.5%	12.8%	13.8%	12.3%		
	9.9% (7.0%,	(1.8%,	(6.2%,	(6.0%,	(4.8%,	(3.9%,	(9.5%,	(10.1%,	(9.3%,	6.5%	
	13.8%)	4.6%)	11.6%)	11.6%)	9.5%)	7.8%)	16.8%)	18.6%)	16.2%)	(3.8%, 10.9%)	
Female		6.4%	10.0%	10.7%	10.0%	11.1%	18.5%	21.2%	15.2%		
	13.0% (9.8%,	(4.6%,	(7.7%,	(8.2%,	(7.5%,	(8.4%,	(14.6%,	(16.9%,	(11.9%,	8.8%	
	17.0%)	8.9%)	12.9%)	13.9%)	13.3%)	14.5%)	23.2%)	26.3%)	19.2%)	(6.4%, 12.0%)	
PR (95% CI)		2.22									
	1.31 (0.85,	(1.25,	1.18 (0.78,	1.29 (0.85,	1.48 (0.94,	2.00 (1.29,	1.45 (1.01,	1.54 (1.05,	1.23 (0.85,	1.35 (0.73,	
	2.03)	3.92)	1.76)	1.96)	2.32)	3.11)	2.10)	2.25)	1.78)	2.50)	
Education											
HS or greater (ref)		4.3%	6.5%	7.3%	6.4%	5.7%	12.8%	14.4%	11.3%		
	9.4% (7.0%,	(2.9%,	(4.8%,	(5.4%,	(4.7%,	(4.1%,	(9.9%,	(11.1%,	(8.7%,	8.0%	
	12.4%)	6.4%)	8.9%)	9.8%)	8.8%)	7.8%)	16.3%)	18.5%)	14.5%)	(5.6%, 11.2%)	
<hs< td=""><td>17.5%</td><td>6.7%</td><td>16.2%</td><td>15.7%</td><td>14.1%</td><td>16.5%</td><td>24.5%</td><td>27.4%</td><td>20.6%</td><td></td></hs<>	17.5%	6.7%	16.2%	15.7%	14.1%	16.5%	24.5%	27.4%	20.6%		
	(12.7%,	(4.7%,	(12.5%,	(11.8%,	(10.1%,	(12.1%,	(18.6%,	(21.2%,	(15.6%,	7.7%	
	23.5%)	9.5%)	20.9%)	20.7%)	19.2%)	22.1%)	31.4%)	34.6%)	26.6%)	(5.1%, 11.5%)	

PR (95% CI)		1.55								
	1.87 (1.22,	(0.91,	2.48 (1.66,	2.16 (1.44,	2.19 (1.40,	2.92 (1.87,	1.91 (1.34,	1.90 (1.34,	1.82 (1.26,	0.97 (0.57,
	2.85)	2.63)	3.73)	3.25)	3.42)	4.54)	2.74)	2.71)	2.63)	1.64)
Race										
White (ref)		4.61%	8.0%	9.2%	7.7%	8.2%	15.5%	17.3%	13.0%	
	11.1% (8.8%,	(3.4%,	(6.3%,	(7.3%,	(5.9%,	(6.4%,	(12.7%,	(14.2%,	(10.5%,	7.8%
	14.0%)	6.3%)	10.1%)	11.5%)	10.0%)	10.5%)	18.9%)	21.0%)	15.9%)	(5.8%, 10.4%)
Black	19.3%	9.9%	26.4%	17.4%	20.6%	17.0%	24.6%	29.4%	26.9%	
	(12.8%,	(6.3%,	(18.2%,	(11.5%,	(13.9%,	(11.5%,	(16.8%,	(20.5%,	(18.6%,	9.7%
	28.1%)	15.3%)	36.6%)	25.6%)	29.5%)	24.5%)	34.6%)	40.3%)	37.2%)	(5.7%, 15.8%)
PR (95% CI)		2.15								
	1.74 (1.10,	(1.25,	3.31 (2.18,	1.90 (1.20,	2.68 (1.70,	2.07 (1.32,	1.59 (1.05,	1.70 (1.15,	2.08 (1.39,	1.24 (0.70,
	2.74)	3.71)	5.03)	3.02)	4.23)	3.26)	2.39)	2.51)	3.10)	2.23)
Diabetes										
No (ref)		5.5%	9.5%	10.2%	9.0%	9.0%	16.8%	19.0%	14.3%	
	12.0% (9.6%,	(4.0%,	(7.5%,	(8.1%,	(7.1%,	(7.2%,	(13.7%,	(15.6%,	(11.7%,	8.7% (6.5%,
	15.0%)	7.4%)	11.8%)	12.7%)	11.3%)	11.4%)	20.3%)	23.0%)	17.4%)	11.6%)
Yes		3.1%	9.2%	8.1%	7.4%	8.2%	14.0%	14.9%	13.1%	
	10.5% (5.5%,	(1.7%,	(6.0%,	(5.0%,	(3.5%,	(4.2%,	(8.5%,	(9.4%,	(8.00%,	3.9% (2.1%,
	19.2%)	5.4%)	13.9%)	13.0%)	14.9%)	15.7%)	22.1%)	23.0%)	20.8%)	7.1%)
PR (95% CI)		0.56								
	0.87 (0.45,	(0.30,	0.98 (0.61,	0.80 (0.47,	0.82 (0.39,	0.91 (0.45,	0.83 (0.50,	0.78 (0.48,	0.92 (0.55,	0.44 (0.22,
	1.70)	1.06)	1.56)	1.35)	1.75)	1.84)	1.39)	1.27)	1.54)	0.87)
Any IADL Limitation										
No (ref)		0.3%	2.7%	1.8%	1.4%	1.7%	6.9%	9.0%	5.2%	
	5.0% (3.3%,	(0.2%,	(1.9%,	(1.1%,	(0.9%,	(1.2%,	(5.0%,	(6.5%,	(3.8%,	3.7% (2.0%,
	7.4%)	0.6%)	3.9%)	2.8%)	2.0%)	2.5%)	9.4%)	12.3%)	7.2%)	6.5%)
Yes	38.6%	23.7%	35.9%	41.5%	37.9%	37.2%	53.4%	55.1%	49.1%	22.7%
	(30.0%,	(17.5%,	(28.0%,	(32.6%,	(29.4%,	(28.8%,	(42.9%,	(44.3%,	(39.1%,	(16.9%,
	47.9%)	31.1%)	44.7%)	50.9%)	47.1%)	46.5%)	63.6%)	65.4%)	59.2%)	29.9%)
PR (95% CI)		73.37	13.16	23.04	27.94	21.38	7.76	6.13	9.42	
	7.72	(36.93,	(8.67,	(13.90,	(17.5,	(13.76,	(5.37,	(4.22,	(6.44,	6.23
	(4.87, 12.24)	145.79)	19.99)	38.19)	44.6)	33.23)	11.21)	8.89)	13.76)	(3.27, 11.86)

Abbreviations: CI, Confidence Interval; PR, Prevalence Ratio

All estimates are weighted using Wave A ADAMS sampling weights.

\*Medicare estimates derived from Medicare-FFS user subset of the common sample (n=517), while all other estimates are derived from the common sample (n=608)

Supplemental Table 3. Adjusted associations between participant characteristics and dementia status by dementia classification strategy											
	Common Sample (n=608)										
	In-Person Existing Algorithms Algorithms Designed to Minimize   Evaluation Race/Ethnicity Differences in Sensitivity   and Specificity										
	ADAMS	H-W	L-K-W	Crimmins	Hurd	Wu	Expert Model	LASSO	Modified Hurd	Medicare 3- year	
	Prevalence Ratio (95% Confidence Interval)										
Age (per 10 years)	1.85 (1.38, 2.48)	1.01 (0.82, 1.25)	1.37 (1.06, 1.76)	1.55 (1.21, 1.98)	1.56 (1.19, 2.05)	1.56 (1.21, 2.01)	2.18 (1.68, 2.82)	1.87 (1.45, 2.39)	2.11 (1.57, 2.84)	2.10 (1.41, 3.14)	
Female	1.11 (0.73, 1.69)	1.75 (1.03, 2.99)	0.99 (0.71, 1.39)	1.02 (0.74, 1.41)	1.19 (0.84, 1.69)	1.72 (1.17, 2.53)	1.20 (0.89, 1.61)	1.33 (0.97, 1.82)	0.98 (0.71, 1.35)	1.17 (0.61, 2.22)	
Less than HS	0.96 (0.67, 1.39)	0.66 (0.45, 0.98)	1.07 (0.76, 1.49)	0.92 (0.67, 1.27)	0.88 (0.65, 1.19)	1.34 (1.00, 1.79)	1.00 (0.75, 1.32)	1.07 (0.80, 1.42)	0.85 (0.63, 1.15)	0.49 (0.29, 0.81)	
Black	1.45 (0.99 <i>,</i> 2.11)	1.96 (1.31, 2.93)	2.57 (1.79, 3.69)	1.53 (1.09, 2.16)	2.20 (1.57, 3.09)	1.55 (1.14, 2.11)	1.33 (0.98, 1.80)	1.42 (1.07, 1.89)	1.77 (1.33, 2.37)	1.35 (0.81, 2.26)	
Diabetes	0.99 (0.60, 1.64)	0.57 (0.29, 1.12)	0.97 (0.58, 1.61)	0.90 (0.51, 1.61)	0.90 (0.62, 1.31)	0.90 (0.66, 1.24)	0.99 (0.69, 1.42)	0.86 (0.61, 1.21)	1.09 (0.75, 1.60)	0.54 (0.27, 1.05)	
Any IADL Limitation	3.09 (1.81 <i>,</i> 5.27)	19.90 (8.20, 48.28)	5.30 (3.25, 8.66)	8.62 (4.63, 16.08)	9.39 (5.33, 16.54)	6.13 (3.52, 10.67)	3.39 (2.18, 5.26)	2.54 (1.56, 4.16)	4.47 (2.81, 7.11)	2.59 (1.19 <i>,</i> 5.61)	
Abbreviations: CI, Confi	dence Interval; F	FS, fee-for-ser	vice; HS, high s	chool; IADL, ins	trumental activity	vities of daily li	ving	ho tablo as well		arsus solf	

All estimates are weighted using Wave A ADAMS sampling weights, and mutually adjusted for all other characteristics listed in the table as well as HRS proxy versus self-respondent status.

Supplemental Table 4. Sensitivity analysis for dementia prevalence by ascertainment strategy and participant characteristics using all available data										
	In-Person		Ex	isting Algorith	ms		Algorith	ms Designed to	Minimize	Medicare,
	Evaluation						Race/Ethnic	in Sensitivity	Any FFS	
								and Specificity	/	
	ADAMS	H-W	L-K-W	Crimmins	Hurd	Wu	Expert	LASSO	Modified	Medicare 3-
	N=751	N=751	N=750	N=717	N=724	N=750	Model	N=655	Hurd	year
							N=745		N=720	N=640
			1	Dement	ia Prevalence (9	95% Confidence	Interval)	1	1	
Overall	13.2%	5.4%	10.2%	12.0%	9.6% (7.8%,	9.8% (8.1%,	18.0%	19.2%	15.6%	9.5%, (7.4%,
	(10.9%,	(4.2%, 6.8%)	(8.6%,	(9.9%,	11.8%)	11.8%)	(15.3%,	(16.1%,	(13.2%,	12.0%)
	15.8%)		12.2%)	14.4%)			21.1%)	22.7%)	18.4%)	
Age										
Under Age 80 (ref)	6.2% (4.2%,	3.0% (1.8%,	6.0% (4.3%,	5.5% (3.6%,	3.4% (2.0%,	4.1% (2.7%,	7.5% (5.3%,	10.8%	5.7% (4.0%,	4.2%, (2.6%,
	9.1%)	5.1%)	8.3%)	8.2%)	5.5%)	6.3%)	10.5%)	(7.8%,	8.0%)	6.8%)
								14.9%)		
Age 80 and over	25.2%	9.5% (7.6%,	17.6%	23.0%	20.4%	19.7%	36.2%	34.6%	33.5%	17.6%,
	(20.6%,	12.0%)	(14.4%,	(18.8%,	(16.4%,	(16.0%,	(30.4%,	(28.6%,	(27.9%,	(13.4%,
	30.4%)		21.3%)	27.9%)	25.2%)	23.9%)	42.4%)	41.2%)	39.5%)	22.6%)
PR (95%CI)	4.07 (2.64,	3.19 (1.79,	2.93 (2.00,	4.20 (2.67,	6.08 (3.54,	4.77 (2.98,	4.84 (3.31,	3.20 (2.21,	5.92 (4.01,	4.14 (2.40,
	6.27)	5.69)	4.29)	6.61)	10.44)	7.65)	7.09)	4.65)	8.75)	7.13)
Gender										
Male (ref)	10.3%	3.8% (2.5%,	9.1% (6.9%,	10.8%	7.4% (5.4%,	6.7% (4.9%,	14.6%	15.3%	13.5%	7.5%, (4.8%,
	(7.6%,	5.6%)	11.9%)	(7.8%,	10.1%)	9.0%)	(11.2%,	(11.4%,	(10.4%,	11.5%)
	13.8%)			14.6%)			18.8%)	20.3%)	17.3%)	
Female		6.5% (4.8%,	11.0%	12.7%	11.0%	11.9%	20.3%	21.8%	17.1%	10.7%,
	(11.9%,	8.7%)	(8.8%,	(10.0%,	(8.4%,	(9.4%,	(16.4%,	(17.5%,	(13.7%,	(8.0%,
	18.9%)	4 72 (4 05	13.8%)	16.1%)	14.3%)	15.0%)	24.8%)	26.8%)	21.1%)	14.2%)
PR (95% CI)	1.46 (1.00,	1.72 (1.05,	1.22 (0.85,	1.18 (0.80,	1.50 (0.99,	1.77 (1.21,	1.39 (1.00,	1.43 (1.00,	1.26 (0.91,	1.43 (0.85,
	2.13)	2.81)	1.74)	1.75)	2.26)	2.60)	1.93)	2.04)	1.76)	2.40)
	10 5%	4 20( /2 00)	6 70/ /5 00/	0.00/ /0.00/	7 60/ (5 70/	C 10/ / 1 C 0/	1.1.4.00	45.00/	12.00/	0.10/ /0.00/
HS or greater (ref)	10.5%	4.2% (2.9%,	6.7% (5.0%,	9.0% (6.8%,	7.6% (5.7%,	6.1% (4.6%,	14.4%	15.3%	13.0%	9.1%, (6.6%,
	(8.0%,	5.9%)	8.8%)	11.9%)	10.2%)	8.1%)	(11.5%,	(11.9%,	(10.3%,	12.4%)
410	13.5%)	0.20/ / 0.00/	10.40/	10.00/	14.20/	10.20/	18.0%)	19.5%)	16.3%)	10.20/
<hs< td=""><td>19.4%</td><td>8.2% (6.0%,</td><td>18.4%</td><td>18.8%</td><td>14.2%</td><td>18.3%</td><td>26.1%</td><td>28.3%</td><td>21.7%</td><td>10.2%,</td></hs<>	19.4%	8.2% (6.0%,	18.4%	18.8%	14.2%	18.3%	26.1%	28.3%	21.7%	10.2%,
	(14.9%,	11.1%)	(14.7%)	(14.0%,	(10.5%,	(14.2%)	(20.0%,	(22.2%)	(17.0%,	(7.2%)
	24.0%)	1 09 (1 24	22.9%)	25.9%)		23.3%)	32.4%)	35.2%)	27.270)	14.5%
PR (95% CI)	1.80 (1.29,	1.98 (1.24,	2.77 (1.93,	2.09 (1.44,	1.85 (1.25,	3.02 (2.07,	1.81 (1.32,	1.85 (1.32,	1.00 (1.20,	1.12 (0.71,
Bace	2.07)	5.17)	3.97)	5.05)	2.73)	+.+±)	2.43)	2.30)	2.31)	1.70)
	12.49/	4 70/ /2 50/		10.00/			47.40(	10.20/		0.00/ /7.40/
white (ref)	12.4%	4.7% (3.5%,	8.5% (6.9%,	10.8%	8.5% (6.7%,	8.9% (7.1%,	17.1%	18.3%	14.5%	9.2%, (7.1%,
	(10.0%,	0.1%)	10.4%)	(8.8%,	10.8%)	11.0%)	(14.3%,	(15.0%,	(12.0%,	11.9%)
	15.1%)			13.3%)			20.4%)	22.0%)	17.4%)	1

	22.20/	42 60/ 10 00/	20.00/	25.20/	24 60/	20.20/	27.40/	20.00/	27.00/	12.40/
Віаск	22.2%	13.6% (8.8%,	29.6%	25.2%	21.6%	20.2%	27.4%	29.6%	27.9%	12.4%,
	(15.4%,	20.5%)	(21.4%,	(17.0%,	(14.9%,	(14.1%,	(19.6%,	(21.1%,	(19.9%,	(7.3%,
	30.9%)		39.4%)	35.5%)	30.1%)	28.2%)	36.9%)	39.9%)	37.5%)	20.1%)
PR (95% CI)	1.79 (1.20,	2.92 (1.76,	3.49 (2.41,	2.32 (1.52,	2.53 (1.65,	2.28 (1.52,	1.60 (1.11,	1.62 (1.12,	1.92 (1.33,	1.34 (0.76,
	2.68)	4.84)	5.04)	3.54)	3.87)	3.43)	2.30)	2.35)	2.77)	2.37)
Diabetes										
No (ref)	13.6%	6.0% (4.7%,	10.3%	12.6%	10.2%	10.3%	18.9%	20.3%	16.4%	10.6%,
	(11.1%,	7.8%)	(8.4%,	(10.2%,	(8.2%,	(8.5%,	(15.8%,	(16.8%,	(13.7%,	(8.2%,
	16.4%)		12.5%)	15.4%)	12.6%)	12.5%)	22.5%)	24.3%)	19.5%)	13.6%)
Yes	11.6%	2.7% (1.5%,	10.1%	9.3% (5.9%,	7.3% (3.7%,	7.6% (4.1%,	13.9%	14.5%	12.5%	4.2%, (2.4%,
	(6.8%,	4.6%)	(6.8%,	14.5%)	13.9%)	13.8%)	(8.9%, 21%)	(9.2%,	(7.9%,	7.3%)
	19.1%)		14.9%)					22.1%)	19.2%)	
PR (95% CI)	0.85 (0.49,	0.44 (0.24,	0.99 (0.64,	0.74 (0.45,	0.72 (0.36,	0.74 (0.39,	0.73 (0.46,	0.72 (0.45,	0.76 (0.47,	0.40 (0.22,
	1.48)	0.80)	1.53)	1.22)	1.44)	1.40)	1.17)	1.15)	1.23)	0.73)
Any IADL Limitation										
No (ref)	5.2% (3.6%,	0.4% (0.2%,	2.8% (2.1%,	2.7% (1.6%,	1.8% (1.2%,	2.1% (1.5%,	8.3% (6.3%,	9.5% (7.0%,	6.4% (4.8%,	4.1%, (2.5%,
	7.3%)	0.7%)	3.9%)	4.4%)	2.6%)	2.9%)	11.0%)	12.9%)	8.5%)	6.6%)
Yes	42.1%	23.4%	37.0%	46.5%	38.1%	37.9%	53.0%	55.3%	49.5%	26.2%,
	(34.1%,	(18.0%,	(29.9%,	(37.9%,	(30.4%,	(30.5%,	(43.9%,	(45.1%,	(40.5%,	(20.1%,
	50.4%)	29.7%)	44.7%)	55.3%)	46.5%)	45.9%)	62.0%)	65.1%)	58.5%)	33.4%)
PR (95% CI)	8.15 (5.45,	57.93	13.05 (9.02,	17.34	21.19	18.23	6.37 (4.58,	5.81 (4.07,	7.70 (5.50,	6.42 (3.72,
	12.2)	(31.13,	18.88)	(10.27,	(13.75,	(12.33,	8.84)	8.29)	10.77)	11.11)
		107.82)		29.26)	32.67)	26.95)				
Abbreviations: CI, Con	fidence Interva	l; PR, Prevalenc	e Ratio				•	•		
All estimates are weig	hted using Wav	ve A ADAMS san	pling weights.							
	0									

	In-Person Evaluation		Existing Algorithms					Algorithms Designed to Minimize Race/Ethnicity Differences in Sensitivity and Specificity				
	ADAMS N=751	H-W N=751	L-K-W N=750	Crimmins N=717	Hurd N=724	Wu N=750	Expert Model N=745	LASSO N=655	Modified Hurd N=720	Medicare 3- year N=640		
		Prevalence Ratio (95% Confidence Interval)										
Age (per 10 years)	1.83 (1.45,	1.08 (0.84,	1.42 (1.14,	1.62 (1.31,	1.76 (1.37,	1.71 (1.35,	2.20 (1.79,	1.74 (1.39,	2.28 (1.78,	1.80 (1.29,		
	2.30)	1.38)	1.78)	2.00)	2.27)	2.19)	2.70)	2.19)	2.93)	2.52)		
Female	1.18 (0.82,	1.39 (0.89,	1.01 (0.75,	0.94 (0.70,	1.17 (0.85,	1.50 (1.07,	1.15 (0.88,	1.21 (0.90,	1.02 (0.76,	1.21 (0.72,		
	1.68)	2.18)	1.36)	1.24)	1.62)	2.10)	1.51)	1.63)	1.37)	2.03)		
Less than HS	0.98 (0.71,	0.76 (0.54,	1.18 (0.87,	0.90 (0.67,	0.80 (0.59,	1.36 (1.03,	1.00 (0.76,	1.03 (0.78,	0.83 (0.63,	0.61 (0.39,		
	1.35)	1.08)	1.59)	1.20)	1.09)	1.80)	1.31)	1.35)	1.09)	0.93)		
Black	1.47 (1.04 <i>,</i>	2.41 (1.60,	2.49 (1.80,	1.80 (1.28,	2.20 (1.56,	1.61 (1.18,	1.33 (1.00,	1.39 (1.06,	1.72 (1.29,	1.41 (0.84,		
	2.09)	3.63)	3.44)	2.54)	3.10)	2.20)	1.79)	1.83)	2.28)	2.38)		
Diabetes	0.97 (0.63 <i>,</i>	0.43 (0.23,	1.00 (0.65,	0.85 (0.54,	0.79 (0.53,	0.83 (0.60,	0.92 (0.66,	0.80 (0.58,	0.99 (0.68,	0.44 (0.23,		
	1.49)	0.79)	1.56)	1.34)	1.18)	1.16)	1.28)	1.12)	1.43)	0.82)		
Any IADL Limitation	3.96 (2.50, 6.29)	22.05 (10.43, 46.62)	5.94 (3.88, 9.11)	7.43 (3.90, 14.14)	8.82 (5.21, 14.92)	6.45 (4.01, 10.39)	2.95 (1.98, 4.39)	2.47 (1.52, 4.02)	3.79 (2.53, 5.69)	3.63 (1.86, 7.07)		
Abbreviations: CI, Confi All estimates are weigh respondent status.	dence Interval; F ted using Wave A	FS, fee-for-ser A ADAMS samp	vice; HS, high s bling weights, a	chool; IADL, ins nd mutually ad	strumental activi justed for all ot	vities of daily liv her characteris	ving stics listed in th	ie table as well	as HRS proxy ve	ersus self-		

Supplemental Table 6. Sensitivity analyses for dementia prevalence by ascertainment strategy and participant characteristics considering alternate look-back periods for Medicare-based dementia ascertainment

	In-Person Evaluation (Common Sample)	Me	dicare Subset, (Any FFS Medi	care)	Medicare Subset (No HMO Medicare)
	ADAMS, n=608	Medicare 1-year, n=510	Medicare 3-year, n=517	Medicare 5-year, n=529	Medicare 3-year, n=460
Overall	11.8% (9.5%, 14.5%)	5.8% (4.3%, 7.6%)	7.9% (6.0%, 10.3%)	8.3% (6.4%, 10.8%)	7.9% (5.9%, 10.6%)
Age					
Under Age 80 (ref)	5.7% (3.6%, 9.0%)	2.1% (1.1%, 3.9%)	3.3% (1.8%, 5.7%)	3.3% (1.9%, 5.6%)	3.1% (1.6%, 5.8%)
Age 80 and over	22.9% (18.2%, 28.4%)	11.8% (8.6%, 16.1%)	15.6% (11.5%, 20.8%)	16.7% (12.4%, 22.1%)	15.5% (11.1%, 21.1%)
PR (95%CI)	3.99 (2.41, 6.60)	5.58 (2.81, 11.10)	4.81 (2.52, 9.17)	5.15 (2.76, 9.64)	5.02 (2.47, 10.20)
Gender					
Male (ref)	9.9% (7.0%, 13.8%)	4.6% (2.8%, 7.5%)	6.5% (3.8%, 10.9%)	7.6% (4.6%, 12.2%)	6.3% (3.5%, 11.0%)
Female	13.0% (9.8%, 17.0%)	6.5% (4.6%, 9.1%)	8.7% (6.4%, 12.0%)	8.8% (6.4%, 11.9%)	9.00% (6.3%, 12.6%)
PR (95% CI)	1.31 (0.85, 2.03)	1.40 (0.77, 2.56)	1.35 (0.73, 2.50)	1.16 (0.65, 2.07)	1.42 (0.73, 2.76)
Education					
<hs (ref)<="" td=""><td>9.4% (7.0%, 12.4%)</td><td>5.9% (4.2%, 8.4%)</td><td>8.0% (5.6%, 11.2%)</td><td>8.00% (5.7%, 11.1%)</td><td>7.8% (5.3%, 11.3%)</td></hs>	9.4% (7.0%, 12.4%)	5.9% (4.2%, 8.4%)	8.0% (5.6%, 11.2%)	8.00% (5.7%, 11.1%)	7.8% (5.3%, 11.3%)
HS or greater	17.5% (12.7%, 23.5%)	5.4% (3.4%, 8.3%)	7.7% (5.1%, 11.5%)	9.1% (6.00%, 13.5%)	8.2% (5.4%, 12.4%)
PR (95% CI)	1.87 (1.22, 2.85)	0.90 (0.52, 1.58)	0.97 (0.57, 1.64)	1.13 (0.67, 1.93)	1.05 (0.60, 1.84)
Race					
White (ref)	11.1% (8.8%, 14.0%)	5.6% (4.2%, 7.6%)	7.8% (5.8%, 10.4%)	8.2% (6.1%, 10.8%)	7.7% (5.6%, 10.6%)
Black	19.3% (12.8%, 28.1%)	7.4% (4.0%, 13.2%)	9.7% (5.7%, 15.8%)	10.2% (6.2%, 16.4%)	10.6% (6.2%, 17.5%)
PR (95% CI)	1.74 (1.10, 2.74)	1.31 (0.68, 2.54)	1.24 (0.70, 2.23)	1.25 (0.71, 2.20)	1.38 (0.75, 2.52)
Diabetes					
No (ref)	12.0% (9.6%, 15.0%)	6.3% (4.7%, 8.5%)	8.7% (6.5%, 11.6%)	9.2% (6.9%, 12.1%)	8.7% (6.3%, 11.9%)
Yes	10.5% (5.5%, 19.2%)	3.0% (1.5%, 6.0%)	3.9% (2.1%, 7.1%)	3.9% (2.1%, 7.1%)	4.1% (2.1%, 7.7%)
PR (95% CI)	0.87 (0.45, 1.70)	0.48 (0.22, 1.01)	0.44 (0.22, 0.87)	0.42 (0.22, 0.82)	0.47 (0.23, 0.96)
Any IADL Limitation					
No (ref)	5.0% (3.3%, 7.4%)	2.1% (1.1%, 4.0%)	3.7% (2.0%, 6.5%)	4.0% (2.3%, 6.9%)	3.7% (2.0%, 6.9%)
Yes	38.6% (30.0%, 47.9%)	18.7% (13.7%, 25.2%)	22.7% (16.9%, 29.9%)	23.7% (17.7%, 30.8%)	22.1% (16.2%, 29.6%)
PR (95% CI)	7.72 (4.87, 12.24)	9.00 (4.35, 18.60)	6.23 (3.27, 11.86)	5.89 (3.20, 10.85)	5.93 (2.96, 11.90)
Abbreviations: CI, Conf All estimates are weigh	fidence Interval; PR, Prevaler nted using Wave A ADAMS sa	nce Ratio ampling weights.			

Supplemental Table 7. Sensitivity analyses for adjusted associations considering alternate look-back periods for Medicare-based dementia

ascertainment										
	In-Person	Medica	Medicare Subset, (Any FFS Medicare)							
	Evaluation				(No HMO					
	(Common Sample)									
	ADAMS, n=608	Medicare 1-year,	Medicare 3-year,							
		n=510	n=517	n=529	n=460					
		Prevalence Ratio (95% Confidence Interval)								
Age (per 10 years)	1.85 (1.38, 2.48)	2.09 (1.25, 3.48)	2.10 (1.41, 3.14)	2.20 (1.49, 3.26)	2.24 (1.46, 3.42)					
Female	1.11 (0.73, 1.69)	1.21 (0.64, 2.29)	1.17 (0.61, 2.22)	1.01 (0.56, 1.83)	1.23 (0.62, 2.47)					
Less than HS	0.96 (0.67, 1.39)	0.40 (0.23, 0.71)	0.49 (0.29, 0.81)	0.57 (0.34, 0.98)	0.47 (0.28, 0.79)					
Black	1.45 (0.99, 2.11)	1.50 (0.86, 2.62)	1.35 (0.81, 2.26)	1.29 (0.76, 2.18)	1.44 (0.84, 2.46)					
Diabetes	0.99 (0.6, 1.64)	0.59 (0.28, 1.26)	0.54 (0.27, 1.05)	0.51 (0.27, 0.99)	0.56 (0.28, 1.12)					
Any IADL Limitation	3.09 (1.81, 5.27)	3.41 (1.27, 9.14)	2.59 (1.19, 5.61)	2.36 (1.11, 5.01)	2.30 (1.06, 5.01)					
Abbreviations: CI, Confidence Interval; FFS, fee-for-service; HMO, health maintenance organization; HS, high school; IADL, instrumental activities of dail										
living										

All estimates are weighted using Wave A ADAMS sampling weights, and mutually adjusted for all other characteristics listed in the table as well as HRS proxy versus self-respondent status.